WO1996037206A1 - Compositions orales de rehydratation a base de farine de riz pour animaux de ferme - Google Patents
Compositions orales de rehydratation a base de farine de riz pour animaux de ferme Download PDFInfo
- Publication number
- WO1996037206A1 WO1996037206A1 PCT/NZ1996/000050 NZ9600050W WO9637206A1 WO 1996037206 A1 WO1996037206 A1 WO 1996037206A1 NZ 9600050 W NZ9600050 W NZ 9600050W WO 9637206 A1 WO9637206 A1 WO 9637206A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- day
- calves
- animals
- grams
- riceflour
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 235000013312 flour Nutrition 0.000 title abstract description 5
- 235000007164 Oryza sativa Nutrition 0.000 title abstract description 4
- 235000009566 rice Nutrition 0.000 title abstract description 4
- 240000007594 Oryza sativa Species 0.000 title description 2
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 21
- 238000009472 formulation Methods 0.000 claims abstract description 15
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 11
- 239000003937 drug carrier Substances 0.000 claims abstract description 8
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 4
- 229940100688 oral solution Drugs 0.000 claims abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
- 239000008103 glucose Substances 0.000 claims description 15
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- 239000003792 electrolyte Substances 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
- 235000004279 alanine Nutrition 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical class CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical class [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 229910019142 PO4 Chemical class 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000010452 phosphate Chemical class 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 159000000001 potassium salts Chemical class 0.000 claims description 2
- 241000209094 Oryza Species 0.000 abstract 2
- 244000309466 calf Species 0.000 description 36
- 238000011282 treatment Methods 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 19
- 239000008267 milk Substances 0.000 description 15
- 235000013336 milk Nutrition 0.000 description 13
- 210000004080 milk Anatomy 0.000 description 13
- 239000012530 fluid Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000702670 Rotavirus Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 235000019820 disodium diphosphate Nutrition 0.000 description 3
- GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013384 milk substitute Nutrition 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- 229940038773 trisodium citrate Drugs 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000019621 digestibility Nutrition 0.000 description 2
- 230000000688 enterotoxigenic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 208000034782 Lid sulcus deepened Diseases 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241000581002 Murex Species 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000310 rehydration solution Substances 0.000 description 1
- 238000009155 rehydration therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/22—Compounds of alkali metals
Definitions
- This invention relates to the treatment of diarrhoea in animals.
- Diarrhoea in farm animals can arise through infection or as a result of stress, for example weaning, transportation etc.
- Conventional treatment of diarrhoea and the prevention of dehydration in farm animals required starvation or the withdrawal of all food for its resolution.
- Glucose was previously orally given with electrolytes. Solutions of bentonite or kaolin have also been used in treating diarrhoea, as they are absorbents.
- LectadePlus® is a commercial formulation comprising dextrose and a mixture of electrolytes.
- the glucose and glycine are actively absorbed from the intestine and thus energises the absorption of sodium and water. The effect is to rapidly dehydrate the animal whilst supplying nutrients and electrolytes. This may even occur against an osmotic pressure gradient between the gut and body fluids.
- the present invention seeks to provide an improved treatment of diarrhoea in animals or one which will at least provide farmers and veterinarians with a useful choice.
- the invention provides a formulation comprising complex carbohydrates, monosaccharides and optionally electrolytes in a pharmaceutically acceptable carrier.
- the invention provides a method of treating diarrhoea in animals suffering therefrom by administering to such animal an oral solution containing complex carbohydrates, monosaccharides and optionally electrolytes in a pharmaceutically acceptable carrier.
- the complex carbohydrate is riceflour, while the pharmaceutically acceptable carrier is water and the monosaccharide is glucose.
- the riceflour is milled to a substantially average micron size of 150 microns with substantially no particle being larger than 250 microns.
- the electrolytes are selected from sodium and potassium salts of chloride, citrate, acetate, bicarbonate and phosphate.
- ingredients may include lactose and alanine.
- the above active ingredients are diluted with warm water and mixed until the contents are well suspended.
- the formulations given in the above examples supply immediate energy to the animal from glucose; plus sustained energy from either lactose or riceflour and starch - sources of energy which can be utilised during the treatment of diarrhoea.
- Glucose supports rapid absorption of electrolytes, including sodium and bicarbonate. This is necessary so that water can be absorbed by the animal to reverse dehydration.
- the formulations of the examples provide energy for maintenance of the central body functions in the absence of food or milk.
- the amino acid alanine assists in the sodium uptake.
- calves (35) qualifying to enter the trial were first drenched with 4 g of sodium bicarbonate in 60ml of water to overcome the protection of abomasal acidity against ingested pathogenic organisms. Calves were then orally dosed with a mixture of 5.6 - 6 x 10 enterotoxigenic Escherichia coli (K99) and 30 mis of faeces collected from clinical cases of calf diarrhoea identified as having a rotavirus aetiology. Faeces were tested and presence of rotavirus confirmed using a Murex Rotavirus Latex Testkit in the Virology Laboratory, Massey University. Stock culture was prepared from E.
- the calves (32) were assigned to three different treatment groups based on their immunoglobulin status assessed by the zinc sulfate turbidity test.
- the two deliveries of calves were given either the test product (Example 1) with LectadePlus® as a control.
- the further deliveries of calves were given either (Example 1), (Example 3) or LectadePlus®.
- Table 2 gives a composition of the three different treatments. All calves received four feeds of the oral rehydration solution (ORS) dissolved in two litres of luke warm water starting in the afternoon of Day T. After these four feeds the ORS's were replaced with two feeds of two litres of 50% milk substitute before being placed on milk substitute feeds for the rest of the trial. Calves which did not drink voluntarily were stomach tubed.
- ORS oral rehydration solution
- Fluid volumes were measured in the morning of Days I, T, U, V, and W. Blood samples were taken at the same intervals for determination of plasma sodium, potassium, albumin, urea, creatinine and glucose. Blood biochemistry was done at MAF Batchelar Laboratories, Palmerston North, New Zealand. Blood samples were also taken into heparinized syringe for blood gas analyses. Syringes were kept on ice for transport to the laboratory. Blood gases were analysed within two hours in the Department of Veterinary Clinical Sciences, Massey University using a blood gas analyser except for those occasions when bloods had to be submitted in the clinical pathology laboratories of the Palmerston North Hospital due to breakdown of the gas analyser in the Veterinary Clinic.
- Haemoglobin concentration, HCO 3 , pH, TCO 2 , actual base excesses were measured.
- PCV's were calculated from haemoglobin concentrations by dividing with the factor 3.3.
- Results were analysed with emphasis on Day U and Day V, as data obtained on these days were collected before the re-introduction of dietary milk. Any observed changes on Day W cannot be solely attributed to the ORS. Statistically significant differences between the three treatment groups were absent before the induction of diarrhoea.
- the example 1 group showed the highest percentage of fully restored fluid components with 64% of the test animals having a restored plasma volume and 50% of the tested animals a restored ECF volume on Day V (Table 3).
- the percentages for the control group (Lectade Plus®) treated groups were 62.5% and 50% and for the example 3 treated group 50% and 17% for plasma volume and ECF respectively.
- the improvement in glucose levels were significantly better in the example 3 group than in the example 1 group or in the control group.
- the serum glucose levels continued to drop after two feeds in the example 1 group before improving on Day V.
- example 3 and example 1 ORS's were reflected by the higher serum sodium concentrations in these groups after treatment. Plasma and ECF volumes were also restored more quickly and effectively in the group receiving the example 1 ORS and initially the example 3 group than in the control group.
- example 1 ORS and example 3 ORS had a beneficial effect in restoring fluid compartments more quickly than in LectadePlus®.
- the high available energy and bi-carbonate sources in example 3 group were more effective in rapidly restoring and maintaining serum bi-carbonate levels than in the control group.
- the inclusion of lactose in example 3 ORS in combination with its hypertonicity had a negative therapeutic effect and a majority of calves in this group suffered a relapse. In contrast there were no relapses in either the example 1 group nor the control group after treatment started.
- example 1 ORS enabled isotonicity to be maintained as well as providing a high energy source utilisable by calves as demonstrated by rising serum glucose and sodium and bicarbonate levels.
- the combination of the high energy level and the high sodium concentration in the example 1 ORS had a faster and better effect in restoring fluid volume.
- example 1 produced an undigested residue at the flour/starch tested. Although the effect of the this was benign, dosages of these starch sources can be lowered to about 70% of those tested to reduce this effect.
- Example 2 formulation has a lowered riceflour content, being replaced by lactose. Lactose as a natural food constituent for the neo-natal calf, can be expected to enhance digestibility.
- diarrhoea scours
- dairy feeds can given with either example 1 ORS or example 2 ORS for one or two days.
- milk can be mixed with example 1 ORS or example 2 ORS prepared solutions for 2-4 meals.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU58475/96A AU5847596A (en) | 1995-05-26 | 1996-05-24 | Rice flour based oral rehydration compositions for farm anim als |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ27222695 | 1995-05-26 | ||
NZ272226 | 1995-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996037206A1 true WO1996037206A1 (fr) | 1996-11-28 |
Family
ID=19925276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NZ1996/000050 WO1996037206A1 (fr) | 1995-05-26 | 1996-05-24 | Compositions orales de rehydratation a base de farine de riz pour animaux de ferme |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5847596A (fr) |
WO (1) | WO1996037206A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998009669A1 (fr) * | 1996-09-03 | 1998-03-12 | The Royal Children's Hospital Foundation | Solution rehydratante per os a base de riz |
AU709607B2 (en) * | 1996-09-03 | 1999-09-02 | Royal Children's Hospital Foundation, The | Rice-based oral rehydration solution |
EP0910359A4 (fr) * | 1996-03-20 | 2003-03-05 | Univ New South Wales | Selection et/ou renforcement de populations de micro-organismes residents dans le tractus gastro-intestinal |
EP2659787A1 (fr) * | 2012-05-04 | 2013-11-06 | BENEO-Orafti S.A. | Procédé d'alimentation d'un porcelet ou d'un veau |
WO2021018938A1 (fr) * | 2019-07-29 | 2021-02-04 | Nutreco Ip Assets B.V. | Composition d'électrolyte et procédés d'utilisation |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5112945A (en) * | 1974-07-19 | 1976-01-31 | Soji Iwadare | Chuchoshokuno seiho |
JPS56148242A (en) * | 1980-03-18 | 1981-11-17 | Nippon Haigou Shiryo Kk | Half wetted feed for domestic animals and poultry |
WO1991015199A1 (fr) * | 1990-04-09 | 1991-10-17 | Medicis Corporation | Composition et procede antidiarrheique |
EP0459108A2 (fr) * | 1990-04-03 | 1991-12-04 | Bristol-Myers Squibb Company | Solution de réhydration orale contenant de la dextrine de riz |
US5120539A (en) * | 1991-01-22 | 1992-06-09 | Doyle W. Boatwright | Amylase-electrolyte oral rehydration method and composition |
JPH05286863A (ja) * | 1992-03-24 | 1993-11-02 | Sandoz Nutrition Ltd | 有機化合物に関する改良 |
US5489440A (en) * | 1995-03-06 | 1996-02-06 | Abbott Laboratories | Rice flour-based oral rehydration solution |
US5498408A (en) * | 1992-09-21 | 1996-03-12 | Sandoz Nutrition Ltd. | Oral rehydration composition |
-
1996
- 1996-05-24 WO PCT/NZ1996/000050 patent/WO1996037206A1/fr active Application Filing
- 1996-05-24 AU AU58475/96A patent/AU5847596A/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5112945A (en) * | 1974-07-19 | 1976-01-31 | Soji Iwadare | Chuchoshokuno seiho |
JPS56148242A (en) * | 1980-03-18 | 1981-11-17 | Nippon Haigou Shiryo Kk | Half wetted feed for domestic animals and poultry |
EP0459108A2 (fr) * | 1990-04-03 | 1991-12-04 | Bristol-Myers Squibb Company | Solution de réhydration orale contenant de la dextrine de riz |
WO1991015199A1 (fr) * | 1990-04-09 | 1991-10-17 | Medicis Corporation | Composition et procede antidiarrheique |
US5120539A (en) * | 1991-01-22 | 1992-06-09 | Doyle W. Boatwright | Amylase-electrolyte oral rehydration method and composition |
WO1992012721A1 (fr) * | 1991-01-22 | 1992-08-06 | Boatwright, Doyle, W. | Procede et appareil de rehydratation orale a base d'electrolyte/une amylase |
JPH05286863A (ja) * | 1992-03-24 | 1993-11-02 | Sandoz Nutrition Ltd | 有機化合物に関する改良 |
US5498408A (en) * | 1992-09-21 | 1996-03-12 | Sandoz Nutrition Ltd. | Oral rehydration composition |
US5489440A (en) * | 1995-03-06 | 1996-02-06 | Abbott Laboratories | Rice flour-based oral rehydration solution |
Non-Patent Citations (19)
Title |
---|
ARCHIVES OF DISEASE IN CHILDHOOD, (1982), Vol. 57, PATRA F.C. et al., "Is Oral Rice Electrolyte Solution Superior to Glucose Electrolyte Solution in Infantile Diarrhoea?", pages 910-12. * |
BMJ, (1992), Vol. 304, GORE S.M. et al., "Impact of Rice Based Oral Rehydration Solution on Stool Output and Duration of Diarrhoea: Meta-Analysis of 13 Clinical Trials", pages 287-91. * |
BRITISH VETERINARY JOURNAL, (1992), Vol. 148, No. 6, MITCHELL A.R. et al., "The Comparitive Effectiveness of Three Commercial Oral Solutions in Correcting Fluid, Electrolyte and Acid Base Disturbances Caused by Calf Diarrhoea", pages 507-22. * |
BULLETIN OF THE WORLD HEALTH ORGANISATION, (1985), Vol. 63, No. 4, MOLLA A.M. et al., "Rice-Based Oral Rehydration Solution Decreases the Stool Volume in Acute Diarrhoea", pages 751-6. * |
DERWENT ABSTRACT, No. 19973X; & JP,A,51 012 945 (IWADARE S), 31 January 1976. * |
DERWENT ABSTRACT, No. 90-013297; & SE,A,88 01143 (JUNGVID H AB), 29 September 1989. * |
DERWENT ABSTRACT, No. 93-383004; & JP,A,05 286 863 (SANDOZ NUTRITION LTD.), 2 November 1993. * |
DISEASE IN CHILDHOOD, (1994), Vol. 71, ISLAM A. et al., "Is Rice Based Oral Rehydration Therapy Effective in Young Infants", pages 19-23. * |
GASTROENTEROLOGY, (1991), Vol. 101, RABBANI G.H. et al., "Short-Chain Glucose Polymer and Anthracene-9-Carboxylic Acid Inhibit Water and Electrolyte Secretion Induced by Dibutyryl Cyckic AMP in the Small Intestine", pages 1046-53. * |
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, (1987), Vol. 6, BHAN M.K. et al., "Efficacy of Mung Bean (Lentil) and Pop Rice Based Rehydration Solutions in Comparison with the Standard Glucose Electrolyte Solution", pages 392-9. * |
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, (1988), Vol. 7, EL-MOUGI et al., "Controlled Clinical Trial on the Efficacy of Rice Powder-Based Oral Rehydration Solution on the Outcome of Acute Diarrhea in Infants", pages 572-6. * |
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, (1989), Vol. 8, MOLLA A.M. et al., "Turning off the Diarrhea: The Role of Food and ORS", pages 81-4. * |
NEW ENGLAND JOURNAL OF MEDICINE, (1988), Vol. 319, No. 20, CARPENTER C.C.J. et al., "Oral-Rehydration Therapy - The Role of Polymeric Substrates", pages 1346-8. * |
NEW ENGLAND JOURNAL OF MEDICINE, (1991), Vol. 324, No. 8, PIZZARRO D. et al., "Rice Based Oral Electrolyte Solutions for the Management of Infantile Diarrhea", pages 517-21. * |
PATENT ABSTRACTS OF JAPAN, Vol. 6, No. 31; & JP,A,56 148 242 (NIPPON HAIGOU SHIRIYOU K.K.), 17 November 1981. * |
THE JOURNAL OF PEDIATRICS, (1990), Vol. 116, No. 6, SLOVEN D.G. et al., "Hydrolysis and Absorption of Glucose Polymers from Rice Compared with Corn in Chronic Diarrhea of Infancy", pages 876-81. * |
THE JOURNAL OF PEDIATRICS, (1991), Vol. 118, No. 4, LEBENTHAL E. and LU R., "Glucose Polymers as an Alternative to Glucose in Oral Rehydration Solutions", pages S62-S69. * |
THE LANCET, 12 June 1982, MOLLA A.M. et al., "Rice Powder Electrolyte Solution as Oral Therapy in Diarrhoea Due to Vibrio Cholerae and Escherichia Coli", pages 1317-19. * |
THE LANCET, 25 January 1992, Vol. 339, "Editorial: Cereal Based Oral Rehydration Solutions - Bridging the Gap Between Fluid and Food", pages 219-20. * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0910359A4 (fr) * | 1996-03-20 | 2003-03-05 | Univ New South Wales | Selection et/ou renforcement de populations de micro-organismes residents dans le tractus gastro-intestinal |
WO1998009669A1 (fr) * | 1996-09-03 | 1998-03-12 | The Royal Children's Hospital Foundation | Solution rehydratante per os a base de riz |
AU709607B2 (en) * | 1996-09-03 | 1999-09-02 | Royal Children's Hospital Foundation, The | Rice-based oral rehydration solution |
EP2659787A1 (fr) * | 2012-05-04 | 2013-11-06 | BENEO-Orafti S.A. | Procédé d'alimentation d'un porcelet ou d'un veau |
WO2014000839A1 (fr) * | 2012-05-04 | 2014-01-03 | Beneo-Orafti S.A. | Procédé pour nourrir un porcelet, un agneau ou un veau |
WO2021018938A1 (fr) * | 2019-07-29 | 2021-02-04 | Nutreco Ip Assets B.V. | Composition d'électrolyte et procédés d'utilisation |
CN114269353A (zh) * | 2019-07-29 | 2022-04-01 | 纽崔克Ip资产有限公司 | 电解质组合物及使用方法 |
Also Published As
Publication number | Publication date |
---|---|
AU5847596A (en) | 1996-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hirschhorn et al. | Progress in oral rehydration therapy | |
Goff et al. | Field trials of an oral calcium propionate paste as an aid to prevent milk fever in periparturient dairy cows | |
US6962718B2 (en) | Compositions for treating animal diseases and syndromes | |
Illek et al. | Blood and tissue selenium concentrations in calves treated with inorganic or organic selenium compounds–a comparison | |
US5028437A (en) | Treatment of animal diarrhoea | |
EP0025269B1 (fr) | Composition vétérinaire contre la diarrhée | |
AU2002311871A1 (en) | Compositions for treating animal diseases and syndromes | |
EP0226332A1 (fr) | Compositions vétérinaires | |
McGee et al. | Effect of age and nutrient restriction pre partum on beef suckler cow serum immunoglobulin concentrations, colostrum yield, composition and immunoglobulin concentration and immune status of their progeny | |
Wang et al. | Effects of monolaurin on intestinal barrier, blood biochemical profile, immunity and antioxidant function in porcine epidemic diarrhoea virus-infected piglets | |
WO1996037206A1 (fr) | Compositions orales de rehydratation a base de farine de riz pour animaux de ferme | |
Dubeski et al. | Effects of B vitamin injections on plasma B vitamin concentrations of feed-restricted beef calves infected with bovine herpesvirus-1 | |
JP2004329110A (ja) | 家畜動物用予防及び/又は治療剤 | |
de Castro Bregadioli et al. | Water intake and feeding with whole milk accentuate metabolic acidosis in calves with induced osmotic diarrhea | |
Cutting et al. | Oral rehydration in diarrhoea: applied pathophysiology | |
Treager et al. | Response to adrenocorticotrophic hormone in clinical scurvy. | |
EP0059057A1 (fr) | Traitement de la diarrhée | |
EP0644767B3 (fr) | Produit veterinaire de rehydratation | |
Archer | Reducing stress in sheep by feeding the seaweed Ascophyllum nodosum | |
Hickmans et al. | A study of cystinuria in two sisters | |
Bouda et al. | Pathophysiology of severe diarrhoea and suggested intravenous fluid therapy in calves of different ages under field conditions | |
Suttle | Non-dietary influences on the mineral requirements of sheep | |
Elitok | The effects of orally given high rate carbohydrate on some pathogens that play an important role in etiology of the diarrhea in calves | |
JAISWAL | EVALUATION OF VARIOUS REHYDRATION ELECTROLYTE SOLUTIONS IN ACUTE CALF DIARRHOEA | |
Glushenko et al. | The use of innovative natural organic substances in the production of broiler meat: Efficiency and safety |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |